Article

Antiandrogen/castration may reduce death risk by 20%

New Orleans--Bicalutamide (Casodex), 50 mg, plus castration leads to an estimated 20% reduction in risk of prostate cancer death versus castration alone, according to results of a historical data analysis presented at the annual of the American Society of Clinical Oncology meeting here.

Related Videos
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Helen L. Bernie, DO, MPH, answers a question during a Zoom video interview
Colin Goudelocke, MD, answers a question during a Zoom video interview
Related Content
Expanded Access Program for recombinant BCG launches at first US site
March 13th 2025

Expanded Access Program for recombinant BCG launches at first US site

Hannah Clarke
There are also 60 sites in the process of launching the EAP.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
House passes bill that includes 57% budget cut to medical research programs
March 12th 2025

House passes bill that includes 57% budget cut to medical research programs

Hannah Clarke
This bill would cut funds for research projects in disease states such as prostate cancer, bladder cancer, kidney cancer, and interstitial cystitis.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Phase 3 trial launches ArteraAI Prostate Test for treatment selection
March 11th 2025

Phase 3 trial launches ArteraAI Prostate Test for treatment selection

Hannah Clarke
The goal of the trial is to improve quality of life by identifying patients who can safely reduce or avoid treatment with hormone therapy.
Adding ADT to SBRT improves progression-free survival in oligorecurrent HSPC
March 10th 2025

Adding ADT to SBRT improves progression-free survival in oligorecurrent HSPC

Hannah Clarke
"Considering that almost all patients in the combined treatment group achieved testosterone recovery at 1 year, the results support that this short term (intermittent) combined approach is an optimal option in selected patients with metachronous oligorecurrent hormone-sensitive prostate cancer," the authors wrote.
© 2025 MJH Life Sciences

All rights reserved.